Coya Therapeutics, Inc. COYA
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -2.95% | -93.66% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -2.95% | -93.66% | |||
| Cost of Revenue | 22.80% | -17.08% | |||
| Gross Profit | -24.48% | -292.19% | |||
| SG&A Expenses | -40.36% | 15.66% | |||
| Depreciation & Amortization | 0.00% | -58.82% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -7.52% | -4.09% | |||
| Operating Income | 7.67% | -79.23% | |||
| Income Before Tax | 7.89% | -26.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 7.89% | -26.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 7.89% | -26.25% | |||
| EBIT | 7.67% | -79.23% | |||
| EBITDA | 7.67% | -79.45% | |||
| EPS Basic | 11.09% | 6.66% | |||
| Normalized Basic EPS | 10.98% | -35.29% | |||
| EPS Diluted | 11.09% | 6.66% | |||
| Normalized Diluted EPS | 10.98% | -35.29% | |||
| Average Basic Shares Outstanding | 3.59% | 35.25% | |||
| Average Diluted Shares Outstanding | 3.59% | 35.25% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||